Expertise
With decades of combined experience in radiopharmaceutical drug development, our team has the expertise and knowledge to reimagine the field and drive our programs forward.
Meet the ExpertsAdvancing Radiopharmaceuticals for Targeted Cancer Treatment
Combining targeted diagnostics and therapeutic delivery to improve outcomes in oncology.
Innovation & Quality
Pioneering the Future of Nuclear Medicine
Cancer diagnoses can disrupt lives. Juniper Biosciences aims to clarify the path ahead with innovative radiopharmaceuticals. We use radioisotopes and high-specificity ligands to diagnose earlier and treat effectively, reducing side effects and enhancing therapeutic impact.
Programs
We are advancing a pipeline of radiopharmaceutical agents across disease states, balancing proven solutions to transform lives and novel theranostics for a brighter tomorrow.
View Pipeline
Purpose
Our vision is to be a leader in radiopharmaceutical innovation – and that starts with bringing the best and brightest to the family. See how you can help us make a difference.
Join the Team
Pipeline & Programs Programs Designed to
Programs Designed to
Transform Patient Outcomes
Balancing clinically proven solutions with novel theranostics across multiple disease states.
| Candidate | Target | Isotope | Pre-Clinical | Phase I | Phase II | Phase III | Reg. Filing |
|---|---|---|---|---|---|---|---|
| JBS-003 (F-MISO) HPV+ Head and Neck Cancer | Hypoxic Tumor Cells | 18F |
|
||||
| JBS-005 α Undisclosed | Undisclosed | Undisc. α-emitter |
|
||||
| JBS-005 β Undisclosed | Undisclosed | Undisc. β-emitter |
|
||||
| JBS-005 γ Undisclosed | Undisclosed | Undisc. PET-emitter |
|
||||
Meet the Team
The Faces Behind Our Science
Alex Agnoletto
CEO, Co-Founder & Board Member
Dr. Indranil Nandi, PhD
COO & Co-Founder
Dr. Kyle Hoffmann, PharmD
Director of Manufacturing, Co-Founder
Dr. Serge Lyashchenko, PharmD
Advisor, Co-Founder & Board Member
Sharon Roded
Advisor, Co-Founder, Board Member
Pietro Bubba Bello
Advisor, Board Member
